Comoros vs Madagascar: Statin use vs. average non-HDL cholesterol levels
Comoros
2.9
in 2018
Madagascar
2.9
in 2018
Comoros rank
154th
Madagascar rank
154th
Statin use vs. average non-HDL cholesterol levels over time
- Comoros
- Madagascar
How they compare
Comoros currently reports 2.9 against 2.9 in Madagascar, a difference of 0.
The two have swapped places 5 times across 39 shared years of data; in 1980 it was Comoros ahead.
Comoros ranks 154th and Madagascar ranks 154th of 191 countries.
Comoros has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Comoros | Madagascar | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.58 | 2.45 | 0.13 | Comoros |
| 1990s | 2.69 | 2.58 | 0.11 | Comoros |
| 2000s | 2.76 | 2.68 | 0.08 | Comoros |
| 2010s | 2.88 | 2.82 | 0.0556 | Comoros |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Comoros or Madagascar?
- Comoros, at 2.9 against 2.9 in Madagascar as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Comoros and Madagascar?
- 0, with Comoros ahead.
- How many years of comparable data are there for Comoros and Madagascar?
- 39 years are reported by both, from 1980 to 2018.
- How do Comoros and Madagascar rank globally for statin use vs. average non-hdl cholesterol levels?
- Comoros ranks 154th and Madagascar ranks 154th of 191 countries.
- Where does this data come from?
- World Health Organization – Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.